Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Consun Pharmaceutical GroupCPHGF +9.09%71 Peter Lynch Fair Value is $1.69 as of Jul. 21, 2026, which is 252% above its 10-year median of 0.48. GuruFocus rates CPHGF with a GF Scoreâ„¢ of 71/100 and a GF Valueâ„¢ of $1.11 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 264 Drug Manufacturers companies, Consun Pharmaceutical Group ranks better than 58.71% on this metric.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Here, as of today, Consun Pharmaceutical Group's PEG is 1. Consun Pharmaceutical Group's 5-Year TTM EBITDA Growth Rate is 9.46.
Consun Pharmaceutical Group's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was $0.18. Therefore, the Peter Lynch Fair Value for today is $1.69.
The historical rank and industry rank for Consun Pharmaceutical Group's Peter Lynch Fair Value or its related term are showing as below:
CPHGF'
s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.24 Med: 0.48 Max: 11.05
Current: 1.02
During the past 13 years, the highest Price to Peter Lynch Fair Value Ratio of Consun Pharmaceutical Group was 11.05. The lowest was 0.24. And the median was 0.48.
CPHGF's Price-to-Peter-Lynch-Fair-Value is ranked better than 58.71% of 264
companies
in the Drug Manufacturers industry
Industry Median: 1.3
vs CPHGF: 1.02
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
Consun Pharmaceutical Group (OTCPK:CPHGF) Peter Lynch Fair Value Explanation
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 9.46 instead of 15 in this case.
Consun Pharmaceutical Group's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value
=
Share Price
/
Peter Lynch Fair Value
=
1.80
/
1.69
=
1.06
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Consun Pharmaceutical Group Peter Lynch Fair Value Related Terms
Consun Pharmaceutical Group Peter Lynch Fair Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Consun Pharmaceutical Group Peter Lynch Fair Value Chart
CPHGF vs ZTS, UTHR: Peter Lynch Fair Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Consun Pharmaceutical Group's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Consun Pharmaceutical Group Price-to-Peter-Lynch-Fair-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Consun Pharmaceutical Group's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:
* The bar in red indicates where Consun Pharmaceutical Group's Price-to-Peter-Lynch-Fair-Value falls into.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Consun Pharmaceutical Group's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was $0.18.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
Consun Pharmaceutical Group (CPHGF) has a Peter Lynch Fair Value of $1.69 as of Jul. 21, 2026. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Consun Pharmaceutical Group and its competitors. This is 252% above median its historical median of 0.48. Over the past decade, Consun Pharmaceutical Group's Peter Lynch Fair Value has ranged from 0.24 to 11.05. According to the industry distribution chart, Consun Pharmaceutical Group ranks #109 out of 264 companies in the Drug Manufacturers industry, placing it in the top 41.3%.
Is Consun Pharmaceutical Group's Peter Lynch Fair Value too high?
Consun Pharmaceutical Group's current Peter Lynch Fair Value of $1.69 is 252% above median its 10-year median of 0.48. Over the past 10 years, this metric has ranged from a low of 0.24 to a high of 11.05. The Drug Manufacturers industry median Peter Lynch Fair Value is 1.30. Consun Pharmaceutical Group's value of $1.69 is 30% above this industry median. Based on the distribution chart, Consun Pharmaceutical Group ranks #109 out of 264 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Consun Pharmaceutical Group has a GF Scoreâ„¢ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Consun Pharmaceutical Group's Peter Lynch Fair Value compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Consun Pharmaceutical Group ranks #109 out of 264 companies for Peter Lynch Fair Value. This puts Consun Pharmaceutical Group in the upper half of its industry. The industry median Peter Lynch Fair Value is 1.30. Consun Pharmaceutical Group's value of $1.69 is 30% above this benchmark. Historically, Consun Pharmaceutical Group's own Peter Lynch Fair Value has ranged from 0.24 to 11.05 over the past decade. While the company's 10-year median is 0.48 vs. the industry median of 1.30, Consun Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Peter Lynch Fair Value for a Drug Manufacturers company?
The median Peter Lynch Fair Value among Drug Manufacturers companies is 1.30, based on 264 companies in the industry. Companies in the top quartile (top 25%) have a Peter Lynch Fair Value significantly above this median, while those in the bottom quartile fall well below. However, Peter Lynch Fair Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Consun Pharmaceutical Group's current Peter Lynch Fair Value of $1.69 is 30% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Peter Lynch Fair Value mean?
A high Peter Lynch Fair Value can signal that a stock is expensive relative to its fundamentals. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Consun Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Peter Lynch Fair Value is 1.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Consun Pharmaceutical Group's current Peter Lynch Fair Value is $1.69, which is 252% above median its own 10-year median of 0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Consun Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Consun Pharmaceutical Group (CPHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.11, compared to a current price of $1.80 — trading 62.2% above its estimated fair value. The current Peter Lynch Fair Value is $1.69, which is 252% above median its 10-year median of 0.48 and 30% above the Drug Manufacturers industry median of 1.30. Consun Pharmaceutical Group's overall GF Score™ is 71/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Peter Lynch Fair Value calculated?
Peter Lynch Fair Value is calculated from a company's financial statements. For Consun Pharmaceutical Group (CPHGF), the current Peter Lynch Fair Value is $1.69 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Consun Pharmaceutical Group (CPHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Consun Pharmaceutical Group stock appears to be overvalued.
The current stock price of $1.80 is trading 62.2% above its estimated GF Value™ of $1.11.
GuruFocus considers Consun Pharmaceutical Group to be Significantly Overvalued.
Key valuation signals for CPHGF:
Peter Lynch Fair Value: $1.69 (252% above median its 10-year median of 0.48)
GF Value™: $1.11 vs. price of $1.80 (62.2% above fair value)
Industry Position: 30% above the Drug Manufacturers median (#109 of 264)
No single metric tells the full story. See the CPHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Company derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
71GF Score
Get the complete analysis for CPHGF
Peter Lynch Fair Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPHGF has been successfully added to your 
